AVXL
NASDAQAnavex Life Sciences Corp.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$2.56-2.11 (-45.38%)
2026-03-122026-06-15
News · 26 weeks31-100%
2025-12-212026-06-14
Mix1890d
- Other10(56%)
- SEC Filings4(22%)
- Insider2(11%)
- Analyst1(6%)
- Earnings1(6%)
Latest news
25 items- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Receives Expected Nasdaq Delinquency NotificationNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Nasdaq Listing Rule") as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026. As indicated in the Notice
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- INSIDERSEC Form 3 filed by new insider Kellmeyer Terrie3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
- SECSEC Form NT 10-Q filed by Anavex Life Sciences Corp.NT 10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive OfficerNEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company's former Senior Vice President of Clinical Development and current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of President and Chief Executive Officer Christopher
- ANALYSTRodman & Renshaw initiated coverage on Anavex with a new price targetRodman & Renshaw initiated coverage of Anavex with a rating of Buy and set a new price target of $20.00
- INSIDERSEC Form 3 filed by new insider Paeger Axel3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
- PRAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's DiseaseFindings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative conditions aligns with blarcamesine's mechanism of action These findings support Anavex's intent to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing unexpectedly common CNS disease mechanisms NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's diseas
- PRAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026. A live audio
- PRAnavex Life Sciences Provides Comprehensive Regulatory UpdateDialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimer's disease Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinson's disease and rare diseases, including Rett syndrome NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's dise
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anavex Life Sciences Corp.SCHEDULE 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's DiseaseNEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA). The decision to withdraw the application f
- PRAnavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's DiseaseNew data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment Oral presentation at the AD/PD™ 2026 Conference Symposium: ‘Advances in AD treatment' highlights the convenience of oral blarcamesine for both patients and families NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurode
- PRNew Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's DiseaseNEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that a new peer-reviewed study published by University of California in Proceedings of the National Academy of Sciences, Nexus1 (Shoff et al., 2026) supports the hypothesis that disruption of neuronal homeostasis—particularly autophagy impairment—acts upstream of amyloid beta (Aβ) and
- PRAnavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 ConferenceNew data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson's model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced
- PRAnavex Life Sciences to Present at the Citizens Life Sciences ConferenceNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the Citizens Life Sciences Conference on Tuesday, March 10th, 2026 at 11:55 AM (ET). About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (NASDAQ:AVXL) is a publicly traded biopharmaceutical
- PRAnavex Life Sciences to Present at the 46th TD Cowen Annual Health Care ConferenceNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026 at 11:50 AM (ET). A live audio webcast will be accessible through the Investors section of the Company's website at www.anav
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Appoints Seasoned Healthcare Leader to Board of DirectorsNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. "We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "Dr. Paeger brings three decades of strong leade
- SECSEC Form 10-Q filed by Anavex Life Sciences Corp.10-Q - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business UpdateCompany to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026. "As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer's disease
AVXL FAQ
6 questionsWhat does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The...Where does AVXL stock trade?
Anavex Life Sciences Corp. (AVXL) is listed on NASDAQ.What sector and industry is AVXL in?
Anavex Life Sciences Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about AVXL?
Anavex Life Sciences Corp. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2000.00 price target on 2026-05-04. Recent price targets range from $1100.00 to $4200.00.What companies are similar to AVXL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare AVXL side-by-side with any of them on Quantisnow.How can I track AVXL on Quantisnow?
Quantisnow aggregates Anavex Life Sciences Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVXL to receive live email and push alerts on every new disclosure.